← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Houston Pharmaceuticals, Inc.
Houston, TX
$2,428,535
Total funding
7
Grants
Funding over time
peak $580.1K · FY2005–16$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$2,428,535 · 7
By mechanism
R44$840,603 · 1
R43$734,383 · 4
R41$554,615 · 1
N43$298,934 · 1
Investigators at Houston Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Preclinical development of WP1066, an effective inhibitor of STAT3 activation for$430,262
R44 · FY2010 · AI
Preclinical development of WP1066, an effective inhibitor of STAT3 activation for$410,341
R44 · FY2011 · AI
WP760 for Malignant Melanoma Therapy$300,000
R41 · FY2005 · CA
IGF::OT::IGF TARGETED RADIONUCLIDE THERAPY OF PANCREATIC CANCER$298,934
N43 · FY2016 · CA
HIGHLY INNOVATED TARGETED THERAPY OF MELANOMA$281,165
R43 · FY2016 · CA
WP760 for Malignant Melanoma Therapy$254,615
R41 · FY2004 · CA
Thermally Targeted Delivery of DOX$179,980
R43 · FY2007 · CA
Inhibition of STAT-3 to stimulate immune function for GBM$146,989
R43 · FY2008 · AI
Development of the first topo II inhibitor for brain tumors$126,249
R43 · FY2007 · CA